Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2021

Open Access 01-12-2021 | Erythropoietin | Research article

The association of erythropoietin-stimulating agents and increased risk for AV-fistula dysfunction in hemodialysis patients. A retrospective analysis

Authors: Anna Wärme, Henrik Hadimeri, Salmir Nasic, Bernd Stegmayr

Published in: BMC Nephrology | Issue 1/2021

Login to get access

Abstract

Background

Patients in maintenance hemodialysis (HD) need a patent vascular access for optimal treatment. The recommended first choice is a native arteriovenous fistula (AVF). Complications of AVF are frequent and include thrombosis, stenosis and infections leading to worsening of dialysis efficacy. Some known risk factors are age, gender and the presence of diabetes mellitus. The aim was to investigate if further risk variables are associated with dysfunctional AVF.

Methods

This retrospective observational study included 153 chronic HD patients (Cases) referred to a total of 473 radiological investigations due to clinically suspected complications of their native AVF. Another group of chronic HD patients (n = 52) who had a native AVF but were without history of previous complications for at least 2 years were controls. Statistical analyses included ANOVA, logistic regression, parametric and non-parametric methods such as Student’s T-test and Mann-Whitney test.

Results

Among Cases, at least one significant stenosis (> 50% of the lumen) was detected in 348 occasions. Subsequent PTA was performed in 248 (71%). Median erythropoiesis-stimulating agent (ESA) weekly doses were higher in Cases than in Controls (8000 vs 5000 IU, p < 0.001). Cases received higher doses of intravenous iron/week than the Controls before the investigation (median 50 mg vs 25 mg, p = 0.004) and low molecular weight heparin (LMWH, p = 0.028). Compared to Controls, Cases had a lower level of parathyroid hormone (median 25 vs 20 ρmol/L, p = 0.009). In patients with diabetes mellitus, HbA1c was higher among Cases than Controls (50 vs 38 mmol/mol, p < 0.001). Multiple regression analysis revealed significant associations between Cases and female gender, prescription of doxazocin, and doses of ESA and LMWH.
There was no difference between the groups regarding hemoglobin, CRP or ferritin.

Conclusion

In conclusion, the present study indicated that the factors associated with AVF problems were high doses of ESA, iron administration, and tendency of thromboembolism (indicated by high LMWH doses); the use of doxazocin prescription, however, requires further investigation.
Literature
1.
Kdoqi N. Kidney F: KDOQI clinical practice guidelines and clinical practice recommendations for Anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 Suppl 3):S11–145.
2.
Robinson BM, Akizawa T, Jager KJ, Kerr PG, Saran R, Pisoni RL. Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. Lancet. 2016;388(10041):294–306.PubMedPubMedCentralCrossRef
3.
Bylsma LC, Gage SM, Reichert H, Dahl SLM, Lawson JH. Arteriovenous fistulae for Haemodialysis: a systematic review and meta-analysis of efficacy and safety outcomes. Eur J Vasc Endovasc Surg. 2017;54(4):513–22.PubMedCrossRef
4.
5.
Rooijens PP, Tordoir JH, Stijnen T, Burgmans JP. Smet de AA, Yo TI: Radiocephalic wrist arteriovenous fistula for hemodialysis: meta-analysis indicates a high primary failure rate. Eur J Vasc Endovasc Surg. 2004;28(6):583–9.PubMedCrossRef
6.
Gameiro J, Ibeas J. Factors affecting arteriovenous fistula dysfunction: a narrative review. J Vasc Access. 2020;21(2):134–47.PubMedCrossRef
7.
Al-Jaishi AA, Oliver MJ, Thomas SM, Lok CE, Zhang JC, Garg AX, Kosa SD, Quinn RR, Moist LM. Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis. Am J Kidney Dis. 2014;63(3):464–78.PubMedCrossRef
8.
Bashar K, Zafar A, Elsheikh S, Healy DA, Clarke-Moloney M, Casserly L, Burke PE, Kavanagh EG, Walsh SR. Predictive parameters of arteriovenous fistula functional maturation in a population of patients with end-stage renal disease. PLoS One. 2015;10(3):e0119958.PubMedPubMedCentralCrossRef
9.
Lok CE, Foley R. Vascular access morbidity and mortality: trends of the last decade. Clin J Am Soc Nephrol. 2013;8(7):1213–9.PubMedCrossRef
10.
Field M, MacNamara K, Bailey G, Jaipersad A, Morgan RH, Pherwani AD. Primary patency rates of AV fistulas and the effect of patient variables. J Vasc Access. 2008;9(1):45–50.PubMedCrossRef
11.
Erkut B, Unlu Y, Ceviz M, Becit N, Ates A, Colak A, Kocak H. Primary arteriovenous fistulas in the forearm for hemodialysis: effect of miscellaneous factors in fistula patency. Ren Fail. 2006;28(4):275–81.PubMedCrossRef
12.
Lee T, Mokrzycki M, Moist L, Maya I, Vazquez M, Lok CE. North American vascular access C: standardized definitions for hemodialysis vascular access. Semin Dial. 2011;24(5):515–24.PubMedPubMedCentralCrossRef
13.
Kazemzadeh GHMM, Ravari H, Daliri M, Hoseini L, Nateghi M. Primary patency rate of native AV fistula: long term follow up. Int J Clin Exp Med. 2012;5(1):173–8.
14.
Hadimeri U, Warme A, Nasic S, Fransson SG, Wigelius A, Stegmayr B. Angiography and phlebography in a hemodialysis population: a retrospective analysis of interventional results. Int J Artif Organs. 2019;42(12):675–83.PubMedPubMedCentralCrossRef
15.
Misskey J, Faulds J, Sidhu R, Baxter K, Gagnon J, Hsiang Y. An age-based comparison of fistula location, patency, and maturation for elderly renal failure patients. J Vasc Surg. 2018;67(5):1491–500.PubMedCrossRef
16.
Kim SM, Ko HK, Noh M, Ko GY, Kim MJ, Kwon TW, Kim HJ, Cho YP. Factors affecting patency following successful percutaneous intervention for dysfunctional hemodialysis vascular access. Ann Vasc Surg. 2018;47:54–61.PubMedCrossRef
17.
Schwab SJ, Raymond JR, Saeed M, Newman GE, Dennis PA, Bollinger RR. Prevention of hemodialysis fistula thrombosis. Early detection of venous stenoses. Kidney Int. 1989;36(4):707–11.PubMedCrossRef
18.
Stegmayr B, Willems C, Groth T, Martins A, Neves NM, Mottaghy K, Remuzzi A, Walpoth B. Arteriovenous access in hemodialysis: a multidisciplinary perspective for future solutions. Int J Artif Organs. 2020:391398820922231.
19.
Patibandla BK, Narra A, Desilva R, Chawla V, Vin Y, Brown RS, Goldfarb-Rumyantzev AS. Disparities in arteriovenous fistula placement in older hemodialysis patients. Hemodial Int. 2014;18(1):118–26.PubMedCrossRef
20.
Marcus RJ, Marcus DA, Sureshkumar KK, Hussain SM, McGill RL. Gender differences in vascular access in hemodialysis patients in the United States: developing strategies for improving access outcome. Gend Med. 2007;4(3):193–204.PubMedCrossRef
21.
Hod T, Desilva RN, Patibandla BK, Vin Y, Brown RS, Goldfarb-Rumyantzev AS. Factors predicting failure of AV "fistula first" policy in the elderly. Hemodial Int. 2014;18(2):507–15.PubMedCrossRef
22.
De Marchi S, Falleti E, Giacomello R, Stel G, Cecchin E, Sepiacci G, Bortolotti N, Zanello F, Gonano F, Bartoli E. Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients. J Am Soc Nephrol. 1996;7(8):1169–77.PubMed
23.
Shurraw S, Zimmerman D. Vascular access complications in daily dialysis: a systematic review of the literature. Minerva Urol Nefrol. 2005;57(3):151–63.PubMed
24.
Irvinn J, Oldman N, Sedgwick P, Chemla E. Do blood pressure levels and other patient characteristics influence native fistula patency? Semin Dial. 2014;27(3):E27–31.PubMedCrossRef
25.
Smith GE, Gohil R, Chetter IC. Factors affecting the patency of arteriovenous fistulas for dialysis access. J Vasc Surg. 2012;55(3):849–55.PubMedCrossRef
26.
Nishizawa Y, Shoji T, Kawagishi T, Morii H. Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. Kidney Int Suppl. 1997;62:S90–2.PubMed
27.
Olsson LF, Odselius R, Ribbe E, Hegbrant J. Evidence of calcium phosphate depositions in stenotic arteriovenous fistulas. Am J Kidney Dis. 2001;38(2):377–83.PubMedCrossRef
28.
Yoshida T, Yamashita M, Horimai C, Hayashi M. High glucose concentration does not modulate the formation of arterial medial calcification in experimental uremic rats. J Vasc Res. 2013;50(6):512–20.PubMedCrossRef
29.
Lanzer P, Boehm M, Sorribas V, Thiriet M, Janzen J, Zeller T, St Hilaire C, Shanahan C. Medial vascular calcification revisited: review and perspectives. Eur Heart J. 2014;35(23):1515–25.PubMedPubMedCentralCrossRef
30.
Warme A, Hadimeri U, Hadimeri H, Nasic S, Stegmayr B. High doses of erythropoietin stimulating agents may be a risk factor for AV-fistula stenosis. Clin Hemorheol Microcirc. 2018.
31.
Wärme A, Hadimeri U, Json Wigelius A, Stegmayr B. A retrospective analysis of dialysis data in patients with native AV-fistula in a Swedish county hospital 2013-14. In: Nordic Society of Nephrology. Stavanger: Nordic Society of Nephrology. p. 2015.
32.
33.
Nishio A, Chhatkuli BP, Ma JZ, Kalantari K. Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients. Blood Purif. 2013;36(1):29–36.PubMedCrossRef
34.
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, et al. Baseline characteristics in the trial to reduce cardiovascular events with Aranesp therapy (TREAT). Am J Kidney Dis. 2009;54(1):59–69.PubMedCrossRef
35.
Leermakers JJ, Bode AS, Vaidya A, van der Sande FM, Evers SM, Tordoir JH. Cost-effectiveness of vascular access for haemodialysis: arteriovenous fistulas versus arteriovenous grafts. Eur J Vasc Endovasc Surg. 2013;45(1):84–92.PubMedCrossRef
36.
Olsha O, Hijazi J, Goldin I, Shemesh D. Vascular access in hemodialysis patients older than 80 years. J Vasc Surg. 2015;61(1):177–83.PubMedCrossRef
37.
Schmidli J, Widmer MK, Basile C, de Donato G, Gallieni M, Gibbons CP, Haage P, Hamilton G, Hedin U, Kamper L et al: Editor's choice - vascular access: 2018 clinical practice guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2018, 55(6):757–818.
38.
Santos EJF, Hortegal EV, Serra HO, Lages JS, Salgado-Filho N, Dos Santos AM. Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study. Braz J Med Biol Res. 2018;51(7):e7288.PubMedPubMedCentralCrossRef
39.
Rattanasompattikul M, Molnar MZ, Zaritsky JJ, Hatamizadeh P, Jing J, Norris KC, Kovesdy CP, Kalantar-Zadeh K. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant. 2013;28(7):1936–45.PubMedCrossRef
40.
Jeong HY, Ko EJ, Kim SH, Lee MJ, Cho HJ, Yang DH, Lee SY. Administration of a High-Dose Erythropoietin-Stimulating Agent in hemodialysis patients is associated with late Arteriovenous fistula failure. Yonsei Med J. 2017;58(4):793–9.PubMedPubMedCentralCrossRef
41.
Wärme A, Hadimeri H, Nasic S, Stegmayr B. The association of erythropoietin-stimulating agents and increased risk for AV-fistula dysfunction in hemodialysis patients. A retrospective analysis. (abstract). International. Journal of Artificial Organs. 2020;43(8):542.
42.
DeFronzo RA. The effect of insulin on renal sodium metabolism. A review with clinical implications. Diabetologia. 1981;21(3):165–71.PubMedCrossRef
43.
Akin D, Ozmen S, Kaya R. A novel factor for primary arteriovenous fistula failure: hyperinsulinism. Ren Fail. 2016;38(8):1206–9.PubMedCrossRef
44.
Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton). 2007;12(4):321–30.CrossRef
45.
Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(4):1077–83.PubMedPubMedCentralCrossRef
46.
Fukuma S, Yamaguchi T, Hashimoto S, Nakai S, Iseki K, Tsubakihara Y, Fukuhara S. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis. 2012;59(1):108–16.PubMedCrossRef
47.
Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis. 1997;29(4):565–8.PubMedCrossRef
48.
Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999;33(1):63–72.PubMedCrossRef
49.
de Lurdes Agostinho Cabrita A, Pinho A, Malho A, Morgado E, Faisca M, Carrasqueira H, Silva AP, Neves PL. Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5. Int Urol Nephrol. 2011;43(3):835–40.PubMedCrossRef
50.
Stegmayr BG, Plum Wirell M. Intravenously administered erythropoietin may cause a direct increase in blood pressure in CAPD patients. Perit Dial Int. 2001;21(3):316–7.PubMedCrossRef
51.
Svensson M, Friberger P, Lundstrom O, Stegmayr B. Activation of FXII during haemodialysis. Scand J Clin Lab Invest. 1996;56(7):649–52.PubMedCrossRef
52.
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, Investigators C. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–98.PubMedCrossRef
53.
Gao S, Ma JJ. Lu C: venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis. Tumour Biol. 2014;35(1):603–13.PubMedCrossRef
54.
Gao D, Ning N, Niu X, Dang Y, Dong X, Wei J, Zhu C. Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Am Heart J. 2012;164(5):715–27 e711.PubMedCrossRef
55.
Streja E, Kovesdy CP, Greenland S, Kopple JD, McAllister CJ, Nissenson AR, Kalantar-Zadeh K. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis. 2008;52(4):727–36.PubMedPubMedCentralCrossRef
56.
Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74(6):791–8.PubMedPubMedCentralCrossRef
57.
Kuo KL, Hung SC, Lee TS, Tarng DC. Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. J Am Soc Nephrol. 2014;25(11):2596–606.PubMedPubMedCentralCrossRef
58.
Rostoker G, Vaziri ND. Iatrogenic iron overload and its potential consequences in patients on hemodialysis. Presse Med. 2017;46(12 Pt 2):e312–28.PubMedCrossRef
59.
KDIGO. Kidney disease: improving global outcomes (KDIGO) Anemia work group. KDIGO clinical practice guideline for Anemia in chronic kidney disease. Kidney International. 2012;(Supplement 2):279–335.
60.
Peters NO, Jay N, Cridlig J, Rostoker G, Frimat L. Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study. BMC Nephrol. 2017;18(1):97.PubMedPubMedCentralCrossRef
61.
Perez-Garcia R, Varas J, Cives A, Martin-Malo A, Aljama P, Ramos R, Pascual J, Stuard S, Canaud B, Merello JI, et al. Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis. Nephrol Dial Transplant. 2018;33(4):690–9.PubMedCrossRef
62.
Kuo KL, Hung SC, Lin YP, Tang CF, Lee TS, Lin CP, Tarng DC. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS One. 2012;7(12):e50295.PubMedPubMedCentralCrossRef
63.
Ikegaya N, Yamamoto T, Takeshita A, Watanabe T, Yonemura K, Miyaji T, Ohishi K, Furuhashi M, Maruyama Y, Hishida A. Elevated erythropoietin receptor and transforming growth factor-beta1 expression in stenotic arteriovenous fistulae used for hemodialysis. J Am Soc Nephrol. 2000;11(5):928–35.PubMed
64.
Dai WD, Zhang DL, Cui WY, Liu WH. Effect of long intermittent hemodialysis on improving dialysis adequacy of maintenance hemodialysis patients. Chin Med J. 2013;126(24):4655–9.PubMed
65.
Ok E, Duman S, Asci G, Tumuklu M, Onen Sertoz O, Kayikcioglu M, Toz H, Adam SM, Yilmaz M, Tonbul HZ, et al. Comparison of 4- and 8-h dialysis sessions in thrice-weekly in-Centre haemodialysis: a prospective, case-controlled study. Nephrol Dial Transplant. 2011;26(4):1287–96.PubMedCrossRef
66.
Holmberg B, Stegmayr BG. Cardiovascular conditions in hemodialysis patients may be worsened by extensive interdialytic weight gain. Hemodial Int. 2009;13(1):27–31.PubMedCrossRef
67.
Ekholm M, Jekell A, Wallen NH, Gigante B, Kahan T. Effects of angiotensin-converting enzyme inhibition and alpha 1-adrenergic receptor blockade on inflammation and hemostasis in human hypertension. J Cardiovasc Pharmacol. 2018;71(4):240–7.PubMedCrossRef
68.
Hernandez RH, Pajuelo JRG, Carvajal AR, Padilla MCA, Dehernandez MJA, Barragan O, Boada JJB. Evidence of an antiplatelet aggregation action of Doxazosin in patients with hypertension - an Exvivo study. Am Heart J. 1991;121(1):395–401.CrossRef
69.
Lee TM, Su SF, Suo WY, Lee CY, Chen MF, Lee YT, Tsai CH. Distension of urinary bladder induces exaggerated coronary constriction in smokers with early atherosclerosis. Am J Physiol Heart Circ Physiol. 2000;279(6):H2838–45.PubMedCrossRef
70.
Qian X, Li M, Wagner MB, Chen G, Song X. Doxazosin stimulates Galectin-3 expression and collagen synthesis in HL-1 Cardiomyocytes independent of protein kinase C pathway. Front Pharmacol. 2016;7:495.PubMedPubMedCentralCrossRef
71.
Chapman N, Chang CL, Dahlof B, Sever PS, Wedel H, Poulter NR, Investigators A. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian cardiac outcomes trial. Circulation. 2008;118(1):42–8.PubMedCrossRef
72.
Asano M, Oguchi K, Saito A, Onishi Y, Yamamoto Y, Fukuhara S, Akiba T, Akizawa T. Intradialytic ultrafiltration volume and vascular access outcomes: a Japan Dialysis outcomes and practice patterns study subanalysis. J Vasc Access. 2016;17(6):489–93.PubMedCrossRef
73.
Salmela B, Hartman J, Peltonen S, Alback A, Lassila R. Thrombophilia and arteriovenous fistula survival in ESRD. Clin J Am Soc Nephrol. 2013;8(6):962–8.PubMedPubMedCentralCrossRef
Metadata
Title
The association of erythropoietin-stimulating agents and increased risk for AV-fistula dysfunction in hemodialysis patients. A retrospective analysis
Authors
Anna Wärme
Henrik Hadimeri
Salmir Nasic
Bernd Stegmayr
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2021
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-020-02209-6

Other articles of this Issue 1/2021

BMC Nephrology 1/2021 Go to the issue

Research article

Low circulating arachidonic acid is associated with macroalbuminuria in diabetic patients: a cross-sectional examination of the KAMOGAWA-DM cohort study

Research

Hepatic cysteine sulphinic acid decarboxylase depletion and defective taurine metabolism in a rat partial nephrectomy model of chronic kidney disease

Research

Comprehensive analysis of IgA nephropathy expression profiles: identification of potential biomarkers and therapeutic agents

Research

Predictors of kidney function recovery among incident ESRD patients

Research

Adrenal function testing in dialysis patients – a review of the literature

Research

Renal outcomes of idiopathic and atypical membranous nephropathy in adult Chinese patients: a single center retrospective cohort study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits